Multiplex Imaging for Better Cancer Diagnosis

Boaz Brill

PentaOmix is developing a system that will revolutionize the way pathologists diagnose cancer by providing all the markers needed for the diagnosis of a certain type of cancer on a single slide, thus providing deeper information, faster response and saving precious tissue.

PentaOmix technology is based on hyper-spectral imaging and is providing significant advantages due to its high scanning speed, simplicity, and robustness.

The product includes a fast optical scanner, optimized staining panels, AI-based image analysis and decision support tools and a viewing tool for the pathologist.

The business model is based on selling the staining panels per patient (reagents), a business model that is acceptable by the customers and can provide revenues of over $1M per tool installed per year.

So far, a convincing PoC of the technology has been demonstrated, including staining and imaging of 8 different markers on the same slide. A retrospective clinical study was done in collaboration with Sheba Medical Center and results have been published in a conference.

Our first product to market is planned to be focused on lung cancer, due to the significant benefit of saving precious tissue by enabling multiple markers to be viewed on a single slide.

To date the company has raise $2M from an EU grant. The company is currently raising seed funding in order to develop an MVP and reach initial installations.